Education Council Disclosures
Education Council Disclosures
COI Review Work Group Disclosures
COI Review Work Group Disclosures
Journal of Urology Editor Disclosures
D. Robert Siemens, MD, FRCSC has nothing to disclose
Author Disclosures
Ashish Kamat, MD
has a financial relationship (Scientific Study or Trial (Oncology)) with Heat Biologics;
financial relationship (Consultant or Advisor (Oncology)) with MDxHealth;
financial relationship (Consultant or Advisor (Oncology)) with Cepheid;
financial relationship (Consultant or Advisor (Oncology)) with Pfizer;
financial relationship (Consultant or Advisor (Oncology)) with BioClin Therapeutics;
financial relationship (Consultant or Advisor (Oncology)) with Roviant;
financial relationship (Consultant or Advisor (Oncology)) with Photocure;
financial relationship (Consultant or Advisor (Oncology)) with Merck;
financial relationship (Scientific Study or Trial (Oncology)) with FerGene;
financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;
financial relationship (Consultant or Advisor (Oncology)) with BMS;
financial relationship (Scientific Study or Trial (General Urology)) with Adolor;
financial relationship (Leadership Position (Specialty Not Specified)) with IBCG;
financial relationship (Scientific Study or Trial (Specialty Not Specified)) with FKD;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Sessen Bio;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Imagin;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with US Biotest;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Asieris;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Medac;
financial relationship (Consultant or Advisor (Oncology)) with Urogen;
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Arquer;
financial relationship (Scientific Study or Trial (Oncology)) with Janssen (+Taris);
financial relationship (Consultant or Advisor (Oncology)) with Fergene;
financial relationship (Consultant or Advisor (Oncology)) with Roche;
financial relationship (Consultant or Advisor (Oncology)) with Engene;
financial relationship (Consultant or Advisor (Oncology)) with Ferring;
financial relationship (Consultant or Advisor (Oncology)) with TMC Innovation;
financial relationship (Consultant or Advisor (Oncology)) with Biological Dynamics;
financial relationship (Consultant or Advisor (Oncology)) with Incyte DSMB;
financial relationship (Consultant or Advisor (Oncology)) with Theralase;
financial relationship (Consultant or Advisor (Oncology)) with Janssen Pharmaceutical ;
financial relationship (Consultant or Advisor (Oncology)) with ProTara;
financial relationship (Consultant or Advisor (Oncology)) with Seattle Genetics;
financial relationship (Consultant or Advisor (Oncology)) with Biological Dynamics;
financial relationship (Consultant or Advisor (Oncology)) with Asieris;
financial relationship (Consultant or Advisor (Oncology)) with Abbott Molecular.
Deepak Pruthi, MD has no relevant financial relationships to disclose at this time.
Udit Singhal, MD has no relevant financial relationships to disclose at this time.
Landon Trost, MD has a financial relationship (Other) with PathRight Medical.
AUA Staff have nothing to disclose.
All relevant financial disclosures have been mitigated.